PubRank

Charles L Sawyers

Author PubWeight™ 364.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002 28.11
2 Integrative genomic profiling of human prostate cancer. Cancer Cell 2010 23.61
3 Molecular determinants of resistance to antiandrogen therapy. Nat Med 2003 18.90
4 Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 15.42
5 Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 13.87
6 Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006 13.54
7 Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002 13.03
8 Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004 11.83
9 Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004 11.29
10 Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010 10.79
11 Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005 10.48
12 Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 2011 7.32
13 Dynamics of chronic myeloid leukaemia. Nature 2005 6.63
14 Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003 6.38
15 Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010 5.59
16 Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008 5.54
17 Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009 5.31
18 Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A 2005 4.70
19 Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med 2006 4.63
20 Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2005 4.44
21 Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest 2007 4.07
22 HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 2004 3.79
23 Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis. Cancer Cell 2008 3.68
24 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002 3.60
25 Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013 3.59
26 Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008 3.56
27 Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 3.51
28 Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013 3.49
29 Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003 3.36
30 Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 2006 3.31
31 Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003 3.24
32 FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011 3.18
33 Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations. Clin Cancer Res 2011 3.15
34 AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem 2003 2.88
35 Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005 2.85
36 Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 2009 2.73
37 ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature 2010 2.65
38 Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2004 2.57
39 ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012 2.51
40 A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 2008 2.48
41 Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007 2.43
42 Transcriptional regulation of a metastasis suppressor gene by Tip60 and beta-catenin complexes. Nature 2005 2.43
43 A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 2002 2.33
44 ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nat Med 2013 2.26
45 Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002 2.15
46 Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013 2.15
47 TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol 2011 2.14
48 Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 2002 2.13
49 Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc Natl Acad Sci U S A 2006 2.13
50 Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 2007 2.04
51 Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002 2.02
52 Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 2006 1.98
53 Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 2003 1.96
54 BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002 1.92
55 JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A 2012 1.88
56 Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov 2012 1.87
57 Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A 2011 1.87
58 A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res 2003 1.83
59 Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line. Cancer Res 2005 1.79
60 Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A 2006 1.77
61 The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008 1.76
62 Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 2012 1.71
63 Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009 1.68
64 Converting cancer therapies into cures: lessons from infectious diseases. Cell 2012 1.65
65 Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3'-deoxy-3'-18F-fluorothymidine PET. J Nucl Med 2005 1.63
66 Cancer: mixing cocktails. Nature 2007 1.57
67 NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002 1.55
68 Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 2002 1.48
69 A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 2011 1.48
70 Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 2002 1.45
71 MYC cooperates with AKT in prostate tumorigenesis and alters sensitivity to mTOR inhibitors. PLoS One 2011 1.38
72 Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010 1.36
73 Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia. PLoS One 2011 1.32
74 Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res 2004 1.21
75 Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 2013 1.21
76 Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging 2002 1.17
77 TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002 1.12
78 Developing standards for breakthrough therapy designation in oncology. Clin Cancer Res 2013 1.09
79 Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002 1.07
80 Annotating MYC status with 89Zr-transferrin imaging. Nat Med 2012 1.06
81 Drug discovery: How melanomas bypass new therapy. Nature 2010 1.05
82 β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest 2013 1.03
83 Amplification and overexpression of prosaposin in prostate cancer. Genes Chromosomes Cancer 2005 0.99
84 Chromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization. Genes Chromosomes Cancer 2002 0.99
85 IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther 2008 0.96
86 AACR Cancer Progress Report 2013. Clin Cancer Res 2013 0.95
87 Even better kinase inhibitors for chronic myeloid leukemia. N Engl J Med 2010 0.94
88 In cancer drug resistance, germline matters too. Nat Med 2012 0.94
89 Calculated resistance in cancer. Nat Med 2005 0.92
90 Treating imatinib-resistant leukemia: the next generation targeted therapies. ScientificWorldJournal 2006 0.91
91 Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet-derived growth factor receptor. J Clin Oncol 2002 0.91
92 Modulators of prostate cancer cell proliferation and viability identified by short-hairpin RNA library screening. PLoS One 2012 0.90
93 Where lies the blame for resistance--tumor or host? Nat Med 2007 0.90
94 Traversing the genomic landscape of prostate cancer from diagnosis to death. Nat Genet 2012 0.90
95 "N of 1" case reports in the era of whole-genome sequencing. J Clin Invest 2013 0.90
96 Cross-species comparisons of cancer signaling. Nat Genet 2005 0.84
97 Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate 2009 0.84
98 The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 2002 0.83
99 AACR Cancer Progress Report 2012. Clin Cancer Res 2012 0.82
100 Coordinate transcriptional regulation by ERG and androgen receptor in fusion-positive prostate cancers. Cancer Cell 2010 0.81
101 MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts. Prostate 2003 0.81
102 Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med 2012 0.80
103 TORward AKTually useful mouse models. Nat Med 2004 0.79
104 Visualization of the interstitial cells of cajal (ICC) network in mice. J Vis Exp 2011 0.79
105 Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging 2014 0.78
106 Integrative Clinical Genomics of Advanced Prostate Cancer. Cell 2015 0.75
107 Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib. Leuk Res 2009 0.75
108 Nineteenth Annual Pezcoller Symposium: hypothesis-driven clinical investigation in cancer. Cancer Res 2007 0.75
109 Cancer drug development. Preface. Curr Top Microbiol Immunol 2012 0.75